Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of $0.08, $0.36 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $21 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.